Walleye Capital LLC Has $1.01 Million Stock Position in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)

Walleye Capital LLC raised its holdings in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSAGet Rating) by 21.9% during the first quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 101,610 shares of the company’s stock after buying an additional 18,246 shares during the quarter. Walleye Capital LLC owned 0.15% of Kiniksa Pharmaceuticals worth $1,010,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. Rice Hall James & Associates LLC grew its holdings in Kiniksa Pharmaceuticals by 13.9% in the 1st quarter. Rice Hall James & Associates LLC now owns 811,922 shares of the company’s stock valued at $8,071,000 after buying an additional 99,115 shares during the last quarter. BNP Paribas Arbitrage SA grew its holdings in shares of Kiniksa Pharmaceuticals by 7.5% during the 1st quarter. BNP Paribas Arbitrage SA now owns 61,197 shares of the company’s stock worth $608,000 after purchasing an additional 4,289 shares in the last quarter. Great Point Partners LLC grew its holdings in shares of Kiniksa Pharmaceuticals by 108.3% during the 1st quarter. Great Point Partners LLC now owns 1,118,067 shares of the company’s stock worth $11,114,000 after purchasing an additional 581,329 shares in the last quarter. Goldman Sachs Group Inc. grew its holdings in shares of Kiniksa Pharmaceuticals by 61.7% during the 1st quarter. Goldman Sachs Group Inc. now owns 936,604 shares of the company’s stock worth $9,310,000 after purchasing an additional 357,387 shares in the last quarter. Finally, PDT Partners LLC acquired a new stake in shares of Kiniksa Pharmaceuticals during the 1st quarter worth approximately $659,000. Institutional investors and hedge funds own 43.22% of the company’s stock.

Kiniksa Pharmaceuticals Trading Up 0.6 %

Shares of NASDAQ:KNSA opened at $10.59 on Tuesday. Kiniksa Pharmaceuticals, Ltd. has a 1-year low of $7.36 and a 1-year high of $15.24. The firm has a market capitalization of $735.70 million, a PE ratio of -6.54 and a beta of -0.18. The business’s 50 day moving average is $11.43 and its 200-day moving average is $10.24.

Kiniksa Pharmaceuticals Company Profile

(Get Rating)

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, which is in Phase 2a clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.

Further Reading

Institutional Ownership by Quarter for Kiniksa Pharmaceuticals (NASDAQ:KNSA)

Receive News & Ratings for Kiniksa Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kiniksa Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.